Alkermes plc.ALKSEarnings & Financial Report
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Revenue
$394.2M
Gross Profit
$342.6M
Operating Profit
$89.1M
Net Profit
$82.8M
Gross Margin
86.9%
Operating Margin
22.6%
Net Margin
21.0%
YoY Growth
4.2%
EPS
$0.49
Alkermes plc. Q3 FY2025 Financial Summary
Alkermes plc. reported revenue of $394.2M (up 4.2% YoY) for Q3 FY2025, with a net profit of $82.8M (down 10.4% YoY) (21.0% margin). Cost of goods sold was $51.6M, operating expenses totaled $253.5M.
Key Financial Metrics
| Total Revenue | $394.2M |
|---|---|
| Net Profit | $82.8M |
| Gross Margin | 86.9% |
| Operating Margin | 22.6% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Alkermes plc. Q3 FY2025 revenue of $394.2M breaks down across 3 segments, led by Products at $317.4M (80.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $317.4M | 80.5% |
| Royalty | $68.0M | 17.2% |
| Manufacturing Revenue | $8.8M | 2.2% |
Alkermes plc. Revenue by Segment — Quarterly Trend
Alkermes plc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Royalty) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | — | $317.4M | — | — |
| Royalty | $65.7M | $68.0M | $66.9M | — |
| Manufacturing Revenue | $3.3M | $8.8M | $16.6M | $17.3M |
Alkermes plc. Annual Revenue by Year
Alkermes plc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.5B |
| 2024 | $1.6B |
| 2023 | $1.7B |
| 2022 | $1.1B |
Alkermes plc. Quarterly Revenue & Net Profit History
Alkermes plc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $384.5M | -10.6% | $49.3M | 12.8% |
| Q3 FY2025 | $394.2M | +4.2% | $82.8M | 21.0% |
| Q2 FY2025 | $390.7M | -2.1% | $87.1M | 22.3% |
| Q1 FY2025 | $306.5M | -12.5% | $22.5M | 7.3% |
| Q4 FY2024 | $430.0M | +13.9% | $146.5M | 34.1% |
| Q3 FY2024 | $378.1M | -0.7% | $92.4M | 24.4% |
| Q2 FY2024 | $399.1M | -35.4% | $91.4M | 22.9% |
| Q1 FY2024 | $350.4M | +21.8% | $36.8M | 10.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $350.4M | $399.1M | $378.1M | $430.0M | $306.5M | $390.7M | $394.2M | $384.5M |
| YoY Growth | 21.8% | -35.4% | -0.7% | 13.9% | -12.5% | -2.1% | 4.2% | -10.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.12B | $2.21B | $2.16B | $2.06B | $2.08B | $2.25B | $2.33B | $2.49B |
| Liabilities | $869.1M | $922.8M | $863.2M | $590.6M | $570.4M | $628.2M | $596.1M | $667.7M |
| Equity | $1.25B | $1.28B | $1.29B | $1.46B | $1.51B | $1.62B | $1.73B | $1.82B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $21.1M | $146.0M | $81.6M | $190.4M | $98.8M | $150.2M | $101.7M | $170.1M |